Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India

OBJECTIVES: Approximately 10%–15% of patients with myasthenia gravis (MG) are refractory to standard treatment. A sizable chunk of these patients is due to muscle-specific tyrosine kinase (MuSK) antibody-positive MG which often runs a severe course with frequent relapses and poor response to convent...

Descripción completa

Detalles Bibliográficos
Autores principales: Sachdeva, Julie, Mahesh, Karthik Vinay, Shree, Ritu, Jain, Gaurav, Kapila, Aastha Takkar, Shashikala, Tirulapati Padmavathi, Goyal, Manoj Kumar, Modi, Manish, Lal, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074426/
https://www.ncbi.nlm.nih.gov/pubmed/32201447
http://dx.doi.org/10.4103/ijp.IJP_333_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074426/
https://www.ncbi.nlm.nih.gov/pubmed/32201447
http://dx.doi.org/10.4103/ijp.IJP_333_18

Ejemplares similares